A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

407

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

January 31, 2012

Conditions
Arthritis, Psoriatic
Interventions
BIOLOGICAL

golimumab

50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg

BIOLOGICAL

Placebo; golimumab

SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg

BIOLOGICAL

golimumab

100 mg sc injections every 4 wks from wk 0 up to 5 yrs

Trial Locations (51)

Unknown

Huntsville

La Jolla

Upland

Aventura

Coeur d'Alene

Kansas City

Wheaton

Worcester

Omaha

Cincinnati

Mayfield

Lake Oswego

Portland

Duncansville

West Reading

Houston

Edmonds

Seattle

Brussels

Ghent

Leuven

Liège

Merksem

Victoria

Winnipeg

St. John's

North Bay

Ottawa

Toronto

Waterloo

Montreal

Sainte-Foy

Sante Foy

Claire

Hamilton Ontario

Newmarket

Saskatoon

Vancouver

Bialystok

Elblag

Kalisz

Poznan

Szczecin

Torun

Warsaw

Santiago de Compostela

Valencia

Glasgow

London

Middlesbrough

Wigan

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

Centocor, Inc.

INDUSTRY